- Benitec Biopharma Inc. reported a **net loss attributable to common shareholders of $37.9 million**, or **$1.05 per basic and diluted share**, for the full year ended June 30, 2025.  **[1808898_0001193125-25-211462_bntc-ex99_1.htm:2]**  This compares to a net loss of $22.4 million, or $1.22 per basic and diluted share, for the prior year.  **[1808898_0001193125-25-211462_bntc-ex99_1.htm:2]** 
- Total expenses for the year ended June 30, 2025, increased to **$41.8 million** from $22.5 million in the previous year, primarily due to higher general and administrative expenses of **$23.4 million** (including **$14.5 million in share-based compensation**) and research and development expenses of **$18.3 million**.  **[1808898_0001193125-25-211462_bntc-ex99_1.htm:1]** **[1808898_0001193125-25-211462_bntc-ex99_1.htm:2]** 
- As of June 30, 2025, the company held **$97.7 million in cash and cash equivalents**.  **[1808898_0001193125-25-211462_bntc-ex99_1.htm:2]** 
- The company anticipates providing **interim clinical study results for Cohort 1** of the BB-301 Phase 1b/2a Treatment Study and expects to begin **enrollment of subjects into Cohort 2** in the fourth calendar quarter of 2025.  **[1808898_0001193125-25-211462_bntc-ex99_1.htm:0]**

Benitec Biopharma (BNTC)